[GSK-3beta: a central kinase for neurodegenerative diseases?].

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Medecine sciences : M/S

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1051/medsci/2010265516PMID 20510151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Induction and spreading of tau pathology in a mouse model of Alzheimer's disease].

  2010cited by this paper
• GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

  2009cited by this paper
• Involvment of Cytosolic and Mitochondrial GSK-3β in Mitochondrial Dysfunction and Neuronal Cell Death of MPTP/MPP+-Treated Neurons

  2009cited by this paper
• Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies

  2009cited by this paper
• [Grafted dopaminergic neurons are targeted by the disease process in Parkinson's disease].

  2009cited by this paper
• Glycogen synthase kinase-3beta is associated with Parkinson's disease.

  2009cited by this paper
• Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

  2009cited by this paper
• α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models

  2009cited by this paper
• Lithium induces clearance of protease resistant prion protein in prion‐infected cells by induction of autophagy

  2009cited by this paper
• Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci).

  2008cited by this paper
• GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer's Disease?

  2008cited by this paper
• Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.

  2008cited by this paper
• Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.

  2008cited by this paper
• Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

  2007cited by this paper
• Neuronal apoptosis and reversible motor deficit in dominant‐negative GSK‐3 conditional transgenic mice

  2007cited by this paper
• Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration

  2007cited by this paper
• LTP inhibits LTD in the hippocampus via regulation of GSK3beta.

  2007cited by this paper
• Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation

  2007cited by this paper
• [Animal models of neurodegenerative diseases].

  2007cited by this paper
• Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.

  2007cited by this paper
• Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3

  2006cited by this paper
• Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta.

  2006cited by this paper
• Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert

  2006cited by this paper
• [Wnt and gastrointestinal stem cells: dangerous connections].

  2006cited by this paper
• Differential effects of chronic lithium and valproate on brain activation in healthy volunteers

  2005cited by this paper
• Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation.

  2005cited by this paper
• Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

  2005cited by this paper
• Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.

  2004cited by this paper
• Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.

  2004cited by this paper
• [Parkinson's disease: what have we learned from the genes responsible for familial forms?].

  2003cited by this paper
• Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3.

  2003cited by this paper
• Mood stabilizers, glycogen synthase kinase-3beta and cell survival.

  2002cited by this paper
• Synphilin-1 Is Developmentally Localized to Synaptic Terminals, and Its Association with Synaptic Vesicles Is Modulated by α-Synuclein*

  2002cited by this paper
• Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.

  2002cited by this paper
• The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

  2001cited by this paper
• Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.

  1999cited by this paper
• Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.

  1998cited by this paper
• Direct association of presenilin-1 with beta-catenin.

  1998cited by this paper
• Tau phosphorylation in transgenic mice expressing glycogen synthase kinase‐3β transgenes

  1997cited by this paper
• In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase‐3β

  1996cited by this paper

• Research progress and perspectives of dual-target inhibitors.

  2025cites this paper
• Oxysterols as Biomarkers of Aging and Disease.

  2024cites this paper
• Discovery of novel quinolin-2-one derivatives as potential GSK-3β inhibitors for treatment of Alzheimer's disease: Pharmacophore-based design, preliminary SAR, in vitro and in vivo biological evaluation.

  2024cites this paper
• Structure-activity relationship of dual inhibitors containing maleimide and imidazole motifs against glutaminyl cyclase and glycogen synthase kinase-3β.

  2024cites this paper
• Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease

  2024cites this paper
• Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease.

  2024cites this paper
• Robust and predictive 3D-QSAR models for predicting the activities of novel oxadiazole derivatives as multifunctional anti-Alzheimer agents

  2024cites this paper
• Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3β.

  2023cites this paper
• Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy

  2021cites this paper
• Behavioral, Biochemical and Histopathological effects of Standardised Pomegranate extract with Vinpocetine, Propolis or Cocoa in a rat model of Parkinson’s disease

  2020cites this paper
• Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.

  2020cites this paper
• Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.

  2020cites this paper
• Neuroinflammation, microglial activation, and glucose metabolism in neurodegenerative diseases.

  2020cites this paper
• K313, a novel benzoxazole derivative, exhibits anti‐inflammatory properties via inhibiting GSK3β activity in LPS‐induced RAW264.7 macrophages

  2018cites this paper
• Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3β/β-Catenin Signaling Pathway

  2017cites this paper
• Efficacy of Morin as a Potential Therapeutic Phytocomponent: Insights into the Mechanism of Action

  2017cites this paper
• The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review.

  2015cites this paper
• Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.

  2015cites this paper
• Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain

  2015cites this paper
• Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.

  2015cites this paper
• Involvement of oxysterols in age-related diseases and ageing processes.

  2014cites this paper
• Subcellular injuries in Alzheimer's disease.

  2014cites this paper
• Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress

  2013cites this paper
• In vivo treatment with diphenyl ditelluride induces neurodegeneration in striatum of young rats: implications of MAPK and Akt pathways.

  2012cites this paper
• Roles of glycogen synthase kinase 3 in Alzheimer's disease.

  2012cites this paper
• In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression.

  2011cites this paper
• α-Tocopherol impairs 7-ketocholesterol-induced caspase-3-dependent apoptosis involving GSK-3 activation and Mcl-1 degradation on 158N murine oligodendrocytes.

  2011cites this paper
• Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer

  2010cites this paper